Cwm LLC Purchases 1,422 Shares of Stryker Co. (NYSE:SYK)

Cwm LLC lifted its position in shares of Stryker Co. (NYSE:SYK) by 11.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 13,979 shares of the medical technology company’s stock after acquiring an additional 1,422 shares during the quarter. Cwm LLC’s holdings in Stryker were worth $4,186,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in SYK. Magellan Asset Management Ltd grew its stake in shares of Stryker by 74,911.8% during the 3rd quarter. Magellan Asset Management Ltd now owns 680,357 shares of the medical technology company’s stock worth $185,921,000 after acquiring an additional 679,450 shares during the period. Barclays PLC lifted its holdings in Stryker by 103.5% during the 3rd quarter. Barclays PLC now owns 1,084,987 shares of the medical technology company’s stock worth $296,493,000 after purchasing an additional 551,798 shares in the last quarter. Morgan Stanley lifted its holdings in Stryker by 4.4% during the 3rd quarter. Morgan Stanley now owns 5,315,227 shares of the medical technology company’s stock worth $1,452,493,000 after purchasing an additional 223,728 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Stryker by 24.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 1,115,955 shares of the medical technology company’s stock worth $304,957,000 after purchasing an additional 217,672 shares in the last quarter. Finally, Ameriprise Financial Inc. lifted its holdings in Stryker by 14.4% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,547,683 shares of the medical technology company’s stock worth $422,099,000 after purchasing an additional 194,715 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Shares of SYK stock opened at $334.89 on Wednesday. The firm has a market cap of $127.42 billion, a P/E ratio of 40.59, a P/E/G ratio of 2.64 and a beta of 0.89. Stryker Co. has a fifty-two week low of $249.98 and a fifty-two week high of $361.41. The business’s 50 day moving average price is $349.64 and its 200-day moving average price is $314.08. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.97 and a current ratio of 1.58.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share for the quarter, topping analysts’ consensus estimates of $3.27 by $0.19. The firm had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. Stryker had a return on equity of 22.99% and a net margin of 15.44%. The business’s quarterly revenue was up 11.8% compared to the same quarter last year. During the same period last year, the company earned $3.00 EPS. On average, equities research analysts anticipate that Stryker Co. will post 11.86 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be paid a $0.80 dividend. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.96%. The ex-dividend date is Wednesday, March 27th. Stryker’s payout ratio is presently 38.79%.

Insider Activity

In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of Stryker stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now owns 3,675 shares in the company, valued at $1,317,414. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of Stryker stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now owns 3,675 shares in the company, valued at $1,317,414. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ronda E. Stryker sold 201,146 shares of the business’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $342.90, for a total value of $68,972,963.40. Following the completion of the transaction, the director now owns 3,755,128 shares of the company’s stock, valued at approximately $1,287,633,391.20. The disclosure for this sale can be found here. Insiders sold a total of 212,109 shares of company stock worth $72,845,768 in the last quarter. 5.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

SYK has been the topic of a number of recent research reports. Citigroup increased their price objective on Stryker from $362.00 to $406.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. TD Cowen raised their price target on Stryker from $365.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, April 11th. Wells Fargo & Company raised their price objective on Stryker from $336.00 to $364.00 and gave the company an “overweight” rating in a report on Wednesday, January 31st. Evercore ISI raised their price objective on Stryker from $340.00 to $370.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Finally, Canaccord Genuity Group raised Stryker from a “hold” rating to a “buy” rating and raised their price objective for the company from $315.00 to $360.00 in a report on Wednesday, January 31st. Three analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $340.67.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.